The agency is missing deadlines and not responding to biotech companies, forcing some to push back clinical trials.

In the face of such pressure, pharmaceutical companies are eager to reduce the cost of drug development so that consumer prices can be lowered without sacrificing profit margin. Fortunately ...

At a political fundraising dinner on Tuesday night, President Donald Trump said he plans to announce tariffs on pharmaceuticals soon. "We're going to tariff our pharmaceuticals, and once we do that, ...

The global biosimulation market, valued at approximately USD 3.1 billion in 2022, is on track to experience significant growth over the next decade. Projected to expand at a compound annual growth ...

Should tariffs on pharmaceutical imports go into effect as President Trump is intimating, it would cause U.S. drug prices to ...

A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9% if passed on, a report commissioned by the ...

LONDON (Reuters) -A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, ...

The global drug discovery services market is projected to grow at a CAGR of 15% from 2025 to 2030. This growth is driven by ...

The U.S. Food and Drug Administration said on Thursday it plans to replace animal testing in the development of monoclonal ...

Among them are experts who navigated a maze of laws to determine if an expensive drug can be sold as a low-cost generic; lab scientists who tested food and drugs for contaminants or deadly ...

Sumitovant Biopharma aims to make a difference in people’s lives by rapidly developing innovative medicines, using a technology-enabled approach to drug ... reduce costs and development ...

Unlike conventional drug discovery, which can take years and cost billions ... Professor of Pharmacological Sciences and Associate Director of the Mount Sinai Center for Therapeutics Discovery ...